May 10, 2023 –           Launch of Atropine Sulfate Injection, USP, 1 mg/10 mL (0.1 mg/mL) – indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.